Skip to content

EBITDA at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
ALN
Alnylam PharmaceuticalsALNY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
Royalty Pharma logo
Royalty PharmaRPRX
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Calculated from Arrowhead Research’s reported figures.

$141.3Mebit+
$6.4MDepreciation Depletion & Amortization
=-$134.89M

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's EBITDA?
Arrowhead Research (ARWR) reported EBITDA of -$134.89M in Q1 2026.
How has Arrowhead Research's EBITDA changed year-over-year?
Arrowhead Research's EBITDA decreased by 134.8% year-over-year, from $387.29M to -$134.89M.
What is the long-term trend for Arrowhead Research's EBITDA?
Over 4 years (2021 to 2025), Arrowhead Research's EBITDA has grown at a -3.5% compound annual growth rate (CAGR), from -$140.77M to $122.27M.
What does EBITDA mean?
Operating cash profit before interest, taxes, and non-cash charges.
How do you interpret EBITDA?
Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
How does EBITDA compare across companies?
Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.